Evinacumab reduces which lipids?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Evinacumab reduces which lipids?

Evinacumab works by inhibiting ANGPTL3, which normally slows the activity of lipoprotein lipase (LPL) and hepatic lipase. When ANGPTL3 is blocked, LPL activity increases, leading to faster clearance of triglyceride-rich particles and reduced production of VLDL. This combination lowers triglycerides and, because less VLDL is available to be converted into LDL particles, there is also a drop in LDL-C. HDL-C is not directly affected by ANGPTL3 inhibition, so its level remains largely unchanged. Therefore, the lipid reductions seen with evinacumab are both LDL-C and triglycerides, rather than HDL-C.

Evinacumab works by inhibiting ANGPTL3, which normally slows the activity of lipoprotein lipase (LPL) and hepatic lipase. When ANGPTL3 is blocked, LPL activity increases, leading to faster clearance of triglyceride-rich particles and reduced production of VLDL. This combination lowers triglycerides and, because less VLDL is available to be converted into LDL particles, there is also a drop in LDL-C. HDL-C is not directly affected by ANGPTL3 inhibition, so its level remains largely unchanged. Therefore, the lipid reductions seen with evinacumab are both LDL-C and triglycerides, rather than HDL-C.

More practice questions